Arvind Chaudhry

4.9k total citations
46 papers, 684 citations indexed

About

Arvind Chaudhry is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Arvind Chaudhry has authored 46 papers receiving a total of 684 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 10 papers in Molecular Biology and 10 papers in Genetics. Recurrent topics in Arvind Chaudhry's work include Cancer Immunotherapy and Biomarkers (11 papers), Chronic Lymphocytic Leukemia Research (10 papers) and CAR-T cell therapy research (8 papers). Arvind Chaudhry is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), Chronic Lymphocytic Leukemia Research (10 papers) and CAR-T cell therapy research (8 papers). Arvind Chaudhry collaborates with scholars based in United States, China and Poland. Arvind Chaudhry's co-authors include Keiko Funa, Kjell Öberg, C H Heldin, Anders Gobl, Carl‐Henrik Heldin, Elizabeth S. Gabitzsch, Joseph P. Balint, Frank R. Jones, Birgitta Eriksson and Younong Xu and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Arvind Chaudhry

43 papers receiving 665 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Arvind Chaudhry United States	12	445	246	205	144	140	46	684
Jeremy Rudnick United States	10	314 0.7×	160 0.7×	178 0.9×	268 1.9×	128 0.9×	36	844
Sivasish Sindiri United States	13	276 0.6×	92 0.4×	230 1.1×	156 1.1×	201 1.4×	23	661
Abrar Choudhury United States	10	254 0.6×	108 0.4×	332 1.6×	87 0.6×	55 0.4×	32	573
Roland Böni Switzerland	16	280 0.6×	111 0.5×	243 1.2×	109 0.8×	61 0.4×	22	603
Jennifer Cain United States	11	470 1.1×	147 0.6×	671 3.3×	181 1.3×	46 0.3×	19	1.1k
Zerrin Onadim United Kingdom	15	490 1.1×	71 0.3×	382 1.9×	83 0.6×	51 0.4×	33	897
Ashley Plant United States	11	166 0.4×	54 0.2×	130 0.6×	193 1.3×	125 0.9×	29	550
Heidi Griesmann Germany	13	333 0.7×	75 0.3×	353 1.7×	111 0.8×	36 0.3×	20	650
Shenghao Jin United States	11	176 0.4×	124 0.5×	494 2.4×	90 0.6×	70 0.5×	21	722
Bruce D. Cohen United States	10	322 0.7×	104 0.4×	420 2.0×	57 0.4×	160 1.1×	12	810

Countries citing papers authored by Arvind Chaudhry

Since Specialization

Citations

This map shows the geographic impact of Arvind Chaudhry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arvind Chaudhry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arvind Chaudhry more than expected).

Fields of papers citing papers by Arvind Chaudhry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arvind Chaudhry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arvind Chaudhry. The network helps show where Arvind Chaudhry may publish in the future.

Co-authorship network of co-authors of Arvind Chaudhry

This figure shows the co-authorship network connecting the top 25 collaborators of Arvind Chaudhry. A scholar is included among the top collaborators of Arvind Chaudhry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arvind Chaudhry. Arvind Chaudhry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Calvo, Emiliano, Valentina Boni, Olivier Dumas, et al.. (2025). Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1/2 non-randomized ARTISTRY-1 trial. Journal for ImmunoTherapy of Cancer. 13(8). e010777–e010777. 2 indexed citations

Hamilton, Erika, Hyo S. Han, Kevin Kalinsky, et al.. (2025). Initial phase 1 dose escalation data for emiltatug ledadotin (Emi-Le), a novel B7-H4-directed dolasynthen antibody-drug conjugate.. Journal of Clinical Oncology. 43(16_suppl). 3009–3009. 1 indexed citations

Vaishampayan, Ulka N., Jameel Muzaffar, Ira Winer, et al.. (2024). Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1). Journal for ImmunoTherapy of Cancer. 12(11). e010143–e010143. 14 indexed citations

Tadmor, Tamar, Toby A. Eyre, Ohad Benjamini, et al.. (2024). BELLWAVE-011: Phase 3 randomized trial of nemtabrutinib versus ibrutinib or acalabrutinib in untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.. Journal of Clinical Oncology. 42(16_suppl). TPS7088–TPS7088. 3 indexed citations

Cheng, Ying, Xiao‐Chen Zhang, Jian Liu, et al.. (2024). YL202/BNT326, a HER3-targeted ADC, in patients with locally advanced or metastatic non-small cell lung cancer and breast cancer: Preliminary results from a first-in-human phase I trial.. Journal of Clinical Oncology. 42(16_suppl). 3034–3034. 5 indexed citations

Oh, Do-Youn, et al.. (2024). Phase 1 trial of TU2218, TGFβ-RI and VEGF-R2 dual inhibitor in monotherapy and combination with pembrolizumab in patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 2613–2613. 1 indexed citations

Tadmor, Tamar, Toby A. Eyre, Ohad Benjamini, et al.. (2024). Phase 3 BELLWAVE-011 Study: Nemtabrutinib Versus Ibrutinib or Acalabrutinib in Previously Untreated Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL). Clinical Lymphoma Myeloma & Leukemia. 24. S182–S182. 1 indexed citations

Tadmor, Tamar, Toby A. Eyre, Ohad Benjamini, et al.. (2024). Nemtabrutinib Versus Ibrutinib or Acalabrutinib for Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: The Phase 3, Open-Label, Randomized Bellwave-011 Study. Blood. 144(Supplement 1). 1875.2–1875.2. 2 indexed citations

Cheng, Ying, Li Wu, Jianwu Shi, et al.. (2024). 57O A phase I/II multicenter, first-in-human study of DB-1311/BNT324 (a novel B7H3 ADC) in patients with advanced solid tumors. Annals of Oncology. 35. S1426–S1426. 4 indexed citations

10.

Zinzani, Pier Luigi, Jiřı́ Mayer, Ohad Benjamini, et al.. (2023). A phase 2 study of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B‐cell malignancies: waveLINE‐006. Hematological Oncology. 41(S2). 564–565. 2 indexed citations

11.

Sharma, Sunil, Alexander Starodub, Nong Xu, et al.. (2023). Preliminary results of a phase 1/2, first-in-human, open-label, dose escalation study of ZL-1211 (anti-Claudin 18.2 mAb) in patients with unresectable or metastatic solid tumors.. Journal of Clinical Oncology. 41(16_suppl). 2537–2537. 6 indexed citations

12.

Hamilton, Erika, Alexander I. Spira, Sylvia Adams, et al.. (2023). XMT-1660: A Phase 1b trial of a B7-H4 targeting antibody drug conjugate (ADC) in endometrial, ovarian, and breast cancers (1250). Gynecologic Oncology. 176. S158–S158.

13.

Hamilton, Erika, Arvind Chaudhry, Alexander I. Spira, et al.. (2023). XMT-1660: A phase 1b trial of a B7-H4 targeted antibody drug conjugate (ADC) in breast, endometrial, and ovarian cancers.. Journal of Clinical Oncology. 41(16_suppl). TPS3154–TPS3154. 6 indexed citations

14.

Meric‐Bernstam, Funda, et al.. (2021). 1869TiP A phase II, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of select HER2-expressing solid tumors (DESTINY-PanTumor02). Annals of Oncology. 32. S1253–S1254. 3 indexed citations

15.

Spira, Alexander I., Paul Conkling, Arvind Chaudhry, et al.. (2020). 1309P ARC-4: Efficacy and safety of AB928 plus carboplatin, pemetrexed and a PD-1 antibody in participants with metastatic non-small cell lung cancer (mNSCLC). Annals of Oncology. 31. S846–S846. 1 indexed citations

16.

Chaudhry, Arvind, et al.. (2018). Prescribing Practices of Endocrine Therapy for Ductal Carcinoma in Situ in British Columbia. Current Oncology. 25(2). 133–138. 6 indexed citations

17.

Bowles, Daniel W., Mark D. Kochenderfer, Allen Lee Cohn, et al.. (2016). A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma. Clinical Colorectal Cancer. 15(4). 337–344.e2. 37 indexed citations

18.

Balint, Joseph P., Elizabeth S. Gabitzsch, Adrian Rice, et al.. (2015). Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer. Cancer Immunology Immunotherapy. 64(8). 977–987. 37 indexed citations

19.

Morse, Michael A., Arvind Chaudhry, Elizabeth S. Gabitzsch, et al.. (2013). Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. Cancer Immunology Immunotherapy. 62(8). 1293–1301. 68 indexed citations

20.

Chaudhry, Arvind, Keiko Funa, & Kjell Öberg. (1993). Expression of Growth Factor Peptides and Their Receptors in Neuroendocrine Tumors of the Digestive System. Acta Oncologica. 32(2). 107–114. 93 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact